Three cells actively deploy precision medicine: expected to introduce China
Sanpower Group acquired a 100% stake in Dendreon. This is the largest transaction record for Chinese companies to acquire US drugs, and it is the first time Chinese companies have acquired original drugs in the United States.
The Chinese private enterprise Sancell Group has new trends in the development of new health industry. On January 9th, US West Coast, Sanpower Group and Valeant, a well-known biopharmaceutical company in the world, reached an equity acquisition agreement in San Francisco to acquire a 100% stake in the latter's US biopharmaceutical company Dendreon, which will become the world's first prostate cancer cell immunotherapy. The owner of Provenge. It is understood that this move sets the largest transaction record for Chinese companies to acquire US drugs, and is the first time Chinese companies have acquired original drugs in the United States.
The world's first prostate cancer cell immunotherapy brings epoch-making significance
The three-cell acquisition of Provenge Cell Immunotherapy was the first autoimmune therapy for prostate cancer that was officially approved by the US FDA on April 29, 2010. It is also the only cellular immunotherapy for the treatment of advanced prostate cancer. Unlike the traditional radiotherapy and surgical methods of cancer treatment, Provenge uses the patient's own immune system to fight against malignant tumors, and re-programs the body's own immune cells to recognize and attack advanced prostate cancer cells, thereby treating prostate cancer. . It can be said that this therapy has epoch-making significance in the field of cancer cell immunotherapy.
For the first time, Provenge systematically verified that the immune system can effectively suppress tumors and prolong life. The median survival of patients receiving Provenge immunotherapy was 25.8 months, while the median survival of patients who did not receive this drug was only 21.7 months, and the median survival increased by 4.1. In most months, most patients can be extended for more than 12 months, especially in patients with prostate cancer who have a low tumor burden. It is reported that Provenge's 4.1-month survival benefit is comparable to other small-molecule oral drugs for the treatment of prostate cancer, but it is safer and safer. The side effects of patients are similar to the symptoms of colds, which can be relieved in 1-2 days, and patients are significantly improved. Quality of Life. Synchronous treatment with Other Drugs is not excluded during treatment.
Provenge has been included in the coverage of major US health insurance, including Medicare (Medical Health Care System), Medicaid (Medical Assistance System) and commercial insurance. 75% of patients can be fully reimbursed, and other patients can be reimbursed more than 80%. Provenge is also the first-line treatment of advanced prostate cancer recommended by the National Comprehensive Cancer Network (NCCN) guidelines.
Digestive System,Lafutudine Tablets,Lafutudine Tablets Digestive System,Lafutudine Tablets For Digestive System
Shandong Qidu Pharmaceutical Co., Ltd. , https://www.qdyypharma.com